|Bid||42.13 x 1800|
|Ask||42.14 x 1200|
|Day's Range||41.59 - 42.19|
|52 Week Range||32.83 - 51.86|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||21.35|
|Earnings Date||Oct. 25, 2021 - Oct. 29, 2021|
|Forward Dividend & Yield||1.56 (3.98%)|
|Ex-Dividend Date||Jul. 29, 2021|
|1y Target Est||46.23|
Johnson & Johnson CFO Joseph J. Wolk joins Yahoo Finance to discuss Johnson & Johnson’s recent earnings, the effectiveness of its vaccine, and the importance of innovation.
If you want to know who really controls Pfizer Inc. ( NYSE:PFE ), then you'll have to look at the makeup of its share...
While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.